These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1142 related items for PubMed ID: 18974200

  • 1. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW, Kim SJ, Choi HJ, Kim KJ, Kim MJ, Kim SH, Lee HJ, Ko JH, Lee YC, Suzuki A, Kim CH.
    Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
    [Abstract] [Full Text] [Related]

  • 2. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
    Jung MH, Lee SH, Ahn EM, Lee YM.
    Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
    [Abstract] [Full Text] [Related]

  • 3. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
    Shin VY, Wu WK, Chu KM, Wong HP, Lam EK, Tai EK, Koo MW, Cho CH.
    Mol Cancer Res; 2005 Nov; 3(11):607-15. PubMed ID: 16317086
    [Abstract] [Full Text] [Related]

  • 4. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC, Wood J, Mandriota SJ, Schnell C, Ferrari S, Mestan J, Zhu Z, Witte L, Pepper MS.
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [Abstract] [Full Text] [Related]

  • 5. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K.
    Cancer Res; 2008 Jun 15; 68(12):4754-62. PubMed ID: 18559522
    [Abstract] [Full Text] [Related]

  • 6. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW, Lien JC, Kuo SC, Huang TF.
    Carcinogenesis; 2012 May 15; 33(5):1022-30. PubMed ID: 22436611
    [Abstract] [Full Text] [Related]

  • 7. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.
    Cancer Res; 2004 May 15; 64(10):3586-92. PubMed ID: 15150116
    [Abstract] [Full Text] [Related]

  • 8. Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2.
    Patel NS, Mathura VS, Bachmeier C, Beaulieu-Abdelahad D, Laporte V, Weeks O, Mullan M, Paris D.
    J Neurochem; 2010 Jan 15; 112(1):66-76. PubMed ID: 19818105
    [Abstract] [Full Text] [Related]

  • 9. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
    LaMontagne KR, Butler J, Borowski VB, Fuentes-Pesquera AR, Blevitt JM, Huang S, Li R, Connolly PJ, Greenberger LM.
    Angiogenesis; 2009 Jan 15; 12(3):287-96. PubMed ID: 19544081
    [Abstract] [Full Text] [Related]

  • 10. Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt.
    Nishi J, Minamino T, Miyauchi H, Nojima A, Tateno K, Okada S, Orimo M, Moriya J, Fong GH, Sunagawa K, Shibuya M, Komuro I.
    Circ Res; 2008 Aug 01; 103(3):261-8. PubMed ID: 18583712
    [Abstract] [Full Text] [Related]

  • 11. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis.
    Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, Repici A, Sturm A, Malesci A, Panes J, Yla-Herttuala S, Fiocchi C, Danese S.
    Gastroenterology; 2009 Feb 01; 136(2):585-95.e5. PubMed ID: 19013462
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI, Calvo A, Stafford J, Cheung M, Kumar R, Philp D, Kleinman HK, Green JE.
    Oncogene; 2005 Jan 27; 24(5):790-800. PubMed ID: 15592523
    [Abstract] [Full Text] [Related]

  • 13. Bee venom inhibits tumor angiogenesis and metastasis by inhibiting tyrosine phosphorylation of VEGFR-2 in LLC-tumor-bearing mice.
    Huh JE, Baek YH, Lee MH, Choi DY, Park DS, Lee JD.
    Cancer Lett; 2010 Jun 01; 292(1):98-110. PubMed ID: 20188461
    [Abstract] [Full Text] [Related]

  • 14. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.
    Clin Cancer Res; 2009 Mar 01; 15(5):1612-22. PubMed ID: 19223496
    [Abstract] [Full Text] [Related]

  • 15. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
    Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO, Chen J.
    Mol Cancer Res; 2002 Nov 01; 1(1):2-11. PubMed ID: 12496364
    [Abstract] [Full Text] [Related]

  • 16. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG, Kim TD, Li G, Yoon WH, Chae CB.
    Clin Cancer Res; 2005 Apr 01; 11(7):2651-61. PubMed ID: 15814646
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
    Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG.
    Cancer Res; 2003 Nov 01; 63(21):7301-9. PubMed ID: 14612527
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf.
    Kalkunte S, Brard L, Granai CO, Swamy N.
    Angiogenesis; 2005 Nov 01; 8(4):349-60. PubMed ID: 16400520
    [Abstract] [Full Text] [Related]

  • 19. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway.
    Li M, Wu S, Liu Z, Zhang W, Xu J, Wang Y, Liu J, Zhang D, Tian H, Li Y, Ye W.
    Biochem Pharmacol; 2012 May 01; 83(9):1251-60. PubMed ID: 22305746
    [Abstract] [Full Text] [Related]

  • 20. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
    Balthasar S, Bergelin N, Löf C, Vainio M, Andersson S, Törnquist K.
    Endocr Relat Cancer; 2008 Jun 01; 15(2):521-34. PubMed ID: 18509004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.